Aclaris reports ATI-052 Phase 1b results in two conditions
Key points
- Aclaris Therapeutics (NASDAQ:ACRS) reported Phase 1b results for ATI-052 in atopic dermatitis and asthma, with both trials meeting their primary safety objective.
- At day 57, the atopic dermatitis trial showed 45% placebo-adjusted improvement in eczema severity, while the asthma trial recorded a 59% reduction in an airway inflammation marker at day 15 versus 15% with placebo.
- Aclaris intends to prioritize a Phase 2b trial of ATI-052 in eosinophilic esophagitis early next year and plans to update its strategy for a potential additional indication.
Aclaris Therapeutics (NASDAQ:ACRS) reported Phase 1b results for ATI-052 in atopic dermatitis and asthma, with both trials meeting their primary safety objectives.
The studies enrolled 14 patients in the atopic dermatitis trial and 16 in the asthma trial, with no Grade 3 or 4 treatment-emergent adverse events, adverse-event discontinuations or cases of conjunctivitis observed.
In the atopic dermatitis study, ATI-052 produced a 45% placebo-adjusted improvement in the Eczema Area and Severity Index by day 57, alongside a 43% placebo-adjusted improvement in itch.
In the asthma study, a single dose reduced exhaled nitric oxide, a marker of airway inflammation, by 59% at day 15, compared with a 15% reduction with placebo, while mean improvement in forced expiratory volume in one second reached 200 milliliters.
Aclaris plans to prioritize a Phase 2b trial of ATI-052 in eosinophilic esophagitis early next year and intends to provide an update on a potential additional indication in the near term.SEO and metadata
Frequently asked questions
More from United States
Armstrong World posts $475.8 million Q3 revenue amid strong growth
Centene reports $45.1 billion Q3 revenue and raises 2026 EPS guidance
Polaris raises 2026 earnings outlook after sales rise 10.9%
Johnson Controls delivers 10% sales growth to $7.1 billion in Q4
Immuron sales soar 9% to AUD$2.2 million in Q1
TransUnion's third-quarter revenue climbs 12%
